From bench top to bedside.
Barinaga
M
M
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017209:Apoptosis; D001665:Binding Sites; D002986:Clinical Trials as Topic; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D051231:Farnesyltranstransferase; D016147:Genes, Tumor Suppressor; D016158:Genes, p53; D015316:Genetic Therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000628:therapy; D009857:Oncogenes; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000276:immunology; D017978:Receptors, Growth Factor / Q000037:antagonists & inhibitors; D018631:ras Proteins / Q000037:antagonists & inhibitors
D019883:Alkyl and Aryl Transferases; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018844:Cyclin-Dependent Kinases; D004791:Enzyme Inhibitors; D051231:Farnesyltranstransferase; D011505:Protein-Tyrosine Kinases; D019253:Proto-Oncogene Proteins c-bcl-2; D018719:Erb-b2 Receptor Tyrosine Kinases; D017978:Receptors, Growth Factor; D018631:ras Proteins